How safe is a ChondroFiller injection for the hip?

The short answer is reassuring. Since ChondroFiller entered clinical use in 2013, more than 19,000 treatments have been recorded globally, with no serious adverse device effects (SADEs) reported and an overall complaint rate of approximately 0.06% — fewer than one in every 1,500 cases — according to the manufacturer's Clinical Evaluation Report (CER Version 09, April 2025). An independent datapoint from a 2025 prospective study by Matta et al. found no significant difference in complication rates between ChondroFiller-treated patients and controls, lending external weight to those figures.

Those numbers merit one honest qualification: they derive primarily from manufacturer-sponsored post-market surveillance and reflect a carefully screened patient population. Specifically, the data apply to people with focal Grade III or IV cartilage defects — the type commonly associated with femoroacetabular impingement (FAI) — in whom the surrounding cartilage borders were healthy and intact. They do not describe outcomes in patients with diffuse hip osteoarthritis, who are generally not suitable candidates.

In short, ChondroFiller injection has a genuinely strong safety record within its intended use. Patient selection is the critical variable, and the sections below explain what the typical side effects look like, where the specific risks lie, and what the hip's anatomy adds to the clinical picture.

Normal reactions in the first few days

For most people, days one to three after a ChondroFiller hip injection follow a predictable pattern: localised swelling around the joint, a temporary flare in soreness, mild warmth, and some stiffness when moving the hip. These are normal physiological responses to intra-articular collagen scaffold placement — the hip joint is reacting to a new biological material, which is exactly the environment needed for the scaffold to begin integrating and recruiting the patient's own repair cells.

None of these reactions indicate that something has gone wrong. They are self-limiting and settle on their own in the majority of cases, typically within two to three days, without any specific treatment beyond rest.

During this window, patients should avoid loading the hip — no prolonged walking, stairs where possible, or any activity that puts weight through the joint. This is consistent with the early phase of the recovery plan regardless of how the hip feels.

A small number of patients notice very little reaction at all; others find the first day or two more uncomfortable than expected. Both are within the normal range.

The practical question — when a symptom is no longer a normal reaction but a signal requiring attention — is covered in the next section.

Risks that need discussing before the procedure

Infection

Infection is the primary risk of any intra-articular injection, including ChondroFiller. It is managed through strict sterile technique throughout the procedure, which substantially reduces the likelihood. The critical distinction for hip patients is recognising when a post-injection reaction has moved beyond the normal window. Escalating redness, warmth, or swelling around the hip joint after day three — rather than settling — are red-flag signals that warrant same-day contact with the clinical team, not a wait-and-see approach.

Allergic reaction

ChondroFiller's collagen scaffold is purified from rat tail tendon — a murine-derived protein. Patients with documented hypersensitivity to rodent proteins are formally screened out before treatment, which is why allergic reactions are rare in appropriately selected candidates. Anyone with a known sensitivity to rodent or collagen proteins should raise this during the pre-treatment assessment; the contraindication is well-established and the screening process is designed to identify it.

Hip-specific anatomical risk

The hip joint sits considerably deeper than more accessible joints, and needle access runs close to surrounding vasculature. Accurate placement of the scaffold matters: misdirection carries a higher consequence here than in a more superficial joint. This is why ultrasound or fluoroscopic guidance is not optional for ChondroFiller hip injection — real-time imaging confirms the needle tip position before the collagen gel is delivered.

All three risks occur at low rates in appropriate candidates, but each requires disclosure before proceeding. Patients should contact their clinical team if symptoms are worsening rather than gradually improving after day three.

Why image guidance is essential for a hip injection

Patients who have previously had injections into the shoulder, a tendon sheath, or another accessible joint may not have needed imaging equipment at all — those are structures an experienced clinician can often approach by anatomical landmark alone. The hip is managed differently, and that difference reflects standard practice for any hip joint injection, not a requirement unique to ChondroFiller.

For a ChondroFiller hip injection, real-time imaging — either ultrasound or fluoroscopy — serves two distinct purposes that go beyond the safe-navigation point covered in the previous section. The second, and equally important, purpose is scaffold placement accuracy. ChondroFiller cures to a stable gel within approximately three to five minutes of delivery; once set, it cannot be repositioned. Confirming correct intra-articular placement before the collagen solution is released therefore matters in a way it simply would not for a corticosteroid or hyaluronic acid injection, where small positional variation carries fewer consequences.

In practice, no operating theatre is required. The appointment is outpatient: the patient lies on a treatment couch, the imaging device is positioned alongside the hip, and the clinician uses the live feed to guide and verify placement before injecting. Local anaesthetic is used to numb the entry point. For most patients, the imaging equipment is the only substantive difference they will notice compared with less technically demanding joint injections — it is there to do two jobs simultaneously: protect the structures around the hip and ensure the scaffold goes exactly where it needs to.

Recovery after a ChondroFiller hip injection

Planning ahead for the weeks after a ChondroFiller hip injection matters as much as the procedure itself — because this is not a pain-relief injection and the recovery reflects that distinction.

The collagen gel sets inside the hip joint within minutes of delivery, as noted during the image-guided placement. What takes considerably longer is maturation: the scaffold needs time to stabilise and to allow the body's own progenitor cells to migrate in and begin the process of endogenous repair. Loading the hip joint fully before that process is under way risks disrupting the scaffold before it has integrated. This is why approximately six weeks of restricted weight-bearing is the expected commitment — not a precaution added arbitrarily, but a mechanical requirement that follows directly from how the treatment works.

Symptom improvement is gradual rather than immediate. Because ChondroFiller works through matrix-induced chondrogenesis — a biological process unfolding over weeks to months — patients should not expect the kind of rapid relief that a corticosteroid injection might provide. Progress is typically measured over the rehabilitation period and beyond, not in the days after the appointment.

A structured rehabilitation plan, agreed with the treating clinician or physiotherapist before the procedure, helps patients navigate the restricted phase safely and prepares the hip for a return to normal loading once the scaffold has had sufficient time to mature.

What the evidence covers — and what is still being studied

Those headline figures are, structurally, safety data — they speak to tolerability, complaint rates, and device effects. The separate question is what the published evidence shows about outcomes, and how much of it applies specifically to the hip rather than to ChondroFiller-treated joints generally.

Imaging and reoperation findings

Post-treatment MRI studies from European cohorts return MOCART scores of 81.6 to 84.3. MOCART is a 100-point imaging scale measuring how completely a scaffold fills a defect and integrates with surrounding native cartilage; scores in that range indicate good-to-excellent structural repair. For comparison, published ChondroFiller reoperation rates of 3–8% sit substantially below figures for microfracture (up to 41%) and ACI or MACI procedures (up to 37%).

Where hip-specific evidence is still developing

Most of the functional outcome data — including IKDC and KOOS scores — originates from knee cohorts. Hip-specific long-term evidence is more limited. The key peer-reviewed study for the hip is Perez-Carro et al. (2021, PMC), which described injectable ChondroFiller as a viable treatment for full-thickness acetabular cartilage defects and reported promising early results; the authors explicitly noted that long-term outcome studies are still needed. That is an honest position for both clinicians and patients to hold when making a treatment decision.

Patient selection is the variable that most shapes what these numbers mean in practice. Among carefully chosen candidates — those with focal Grade III/IV defects and intact surrounding cartilage borders — around 70–85% achieve meaningful symptom relief. Patients with advanced diffuse hip osteoarthritis (Tönnis grade 2–3) are generally not suited to a scaffold approach and should expect a different discussion about their options.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.